Top

Current Diabetes Reports

Published in:

Open Access 01-10-2017 | Obesity (J McCaffery, Section Editor)

Weight Management in Patients with Type 1 Diabetes and Obesity

Authors: Adham Mottalib, Megan Kasetty, Jessica Y. Mar, Taha Elseaidy, Sahar Ashrafzadeh, Osama Hamdy

Published in: Current Diabetes Reports | Issue 10/2017

Abstract

Purpose of review

Patients with type 1 diabetes (T1D) are typically viewed as lean individuals. However, recent reports showed that their obesity rate surpassed that of the general population. Patients with T1D who show clinical signs of type 2 diabetes such as obesity and insulin resistance are considered to have “double diabetes.” This review explains the mechanisms of weight gain in patients with T1D and how to manage it.

Recent findings

Weight management in T1D can be successfully achieved in real-world clinical practice.

Summary

Nutrition therapy includes reducing energy intake and providing a structured nutrition plan that is lower in carbohydrates and glycemic index and higher in fiber and lean protein. The exercise plan should include combination stretching as well as aerobic and resistance exercises to maintain muscle mass. Dynamic adjustment of insulin doses is necessary during weight management. Addition of anti-obesity medications may be considered. If medical weight reduction is not achieved, bariatric surgery may also be considered.

Kjær IGH, Kolle E, Hansen BH, Anderssen SA, Torstveit MK. Obesity prevalence in Norwegian adults assessed by body mass index, waist circumference and fat mass percentage. Clinical Obesity. 2015;5(4):211–8. doi:10.1111/cob.12100.PubMedCrossRef

•• Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284-91. doi:10.1001/jama.2016.6458. This report utilizes data from the National Health and Nutrition Examination Survey (NHANES) to describe the alarming changes in obesity trends in the US.

Ghosh A, Charlton KE, Batterham MJ. Socioeconomic disadvantage and its implications for population health planning of obesity and overweight, using cross-sectional data from general practices from a regional catchment in Australia. BMJ Open. 2016;6(5):e010405. doi:10.1136/bmjopen-2015-010405.PubMedPubMedCentralCrossRef

Szadkowska A, Madej A, Ziolkowska K, Szymanska M, Jeziorny K, Mianowska B, et al. Gender and age-dependent effect of type 1 diabetes on obesity and altered body composition in young adults. Annals of Agricultural and Environmental Medicine: AAEM. 2015;22(1):124–8. doi:10.5604/12321966.1141381.PubMedCrossRef

Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27(4):398–404. doi:10.1111/j.1464-5491.2010.02956.x.PubMedPubMedCentralCrossRef

Chillaron JJ, Benaiges D, Mane L, Pedro-Botet J, Flores Le-Roux JA. Obesity and type 1 diabetes mellitus management. Minerva Endocrinol. 2015;40(1):53–60.PubMed

•• de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843–63. doi:10.2337/dc14-1720. This report focuses on the importance of cardiovascular disease in patients with T1D PubMedPubMedCentralCrossRef

Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59(12):3216–22. doi:10.2337/db10-0862.PubMedPubMedCentralCrossRef

Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799–812. doi:10.1111/j.1463-1326.2006.00686.x.PubMedCrossRef

10.

Valla V. Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Exp Diabetes Res. 2010;2010:178372. doi:10.1155/2010/178372.PubMedPubMedCentralCrossRef

11.

Jacob AN, Salinas K, Adams-Huet B, Raskin P. Potential causes of weight gain in type 1 diabetes mellitus. Diabetes Obes Metab. 2006;8(4):404–11. doi:10.1111/j.1463-1326.2005.00515.x.PubMedCrossRef

12.

Giuffrida FM, Bulcao C, Cobas RA, Negrato CA, Gomes MB, Dib SA. Double-diabetes in a real-world sample of 2711 individuals: associated with insulin treatment or part of the heterogeneity of type 1 diabetes? Diabetol Metab Syndr. 2016;8:28. doi:10.1186/s13098-016-0143-7.PubMedPubMedCentralCrossRef

13.

DCCTResearchGroup. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75(14):894–903.CrossRef

14.

Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. The Cochrane database of systematic reviews. 2010;1:CD005103. doi:10.1002/14651858.CD005103.pub2.

15.

Williams KV, Erbey JR, Becker D, Orchard TJ. Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. The Epidemiology of Diabetes Complications Study. Diabetes Care. 1999;22(7):1084–91.PubMedCrossRef

16.

•• Schechter R, Reutrakul S. Management of severe insulin resistance in patients with type 1 diabetes. Current diabetes reports. 2015;15(10):1–12. doi:10.1007/s11892-015-0641-2. This review describes pharmacological therapy for patients with T1D and insulin resistance CrossRef

17.

Bush MA. Intensive diabetes therapy and body weight: focus on insulin detemir. Endocrinol Metab Clin N Am. 2007;36(Suppl 1):33–44.CrossRef

18.

• Timar R, Timar B, Degeratu D, Serafinceanu C, Oancea C. Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus. J Int Med Res. 2014;42(5):1131–8. doi:10.1177/0300060514541829. This study investigates the prevalence of metabolic syndrome and evaluates various inflammatory markers in patients with T1D PubMedCrossRef

19.

Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 2007;92(9):3719–27. doi:10.1210/jc.2007-0349.PubMedCrossRef

20.

Barchetta I, Alessandri C, Bertoccini L, Cimini FA, Taverniti L, Di Franco M, et al. Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. European Journal of Endocrinology/European Federation of Endocrine Societies. 2016;174(2):187–92. doi:10.1530/EJE-15-0791.CrossRef

21.

Colberg SR, Laan R, Dassau E, Kerr D. Physical activity and type 1 diabetes: time for a rewire? Journal of Diabetes Science and Technology. 2015;9(3):609–18. doi:10.1177/1932296814566231.PubMedPubMedCentralCrossRef

22.

Burr JF, Shephard RJ, Riddell MC. Physical activity in type 1 diabetes mellitus: assessing risks for physical activity clearance and prescription. Can Fam Physician. 2012;58(5):533–5.PubMedPubMedCentral

23.

Francescato MP, Stel G, Stenner E, Geat M. Prolonged exercise in type 1 diabetes: performance of a customizable algorithm to estimate the carbohydrate supplements to minimize glycemic imbalances. PLoS One. 2015;10(4):e0125220. doi:10.1371/journal.pone.0125220.PubMedPubMedCentralCrossRef

24.

ADA. Foundations of care and comprehensive medical evaluation. Sec. 3. In standards of medical care in diabetes—2016. Diabetes Care. 2016;39(Suppl 1):S23–35. doi:10.2337/dc16-S006.

25.

Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359(3):229–41. doi:10.1056/NEJMoa0708681.PubMedCrossRef

26.

Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green A, et al. A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. Am J Clin Nutr. 2009;89(5):1588S–96S. doi:10.3945/ajcn.2009.26736H.PubMedPubMedCentralCrossRef

27.

Shirani F, Salehi-Abargouei A, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH) diet on some risk for developing type 2 diabetes: a systematic review and meta-analysis on controlled clinical trials. Nutrition. 2013;29(7–8):939–47. doi:10.1016/j.nut.2012.12.021.PubMedCrossRef

28.

Lee YM, Kim SA, Lee IK, Kim JG, Park KG, Jeong JY, et al. Effect of a brown rice based vegan diet and conventional diabetic diet on glycemic control of patients with type 2 diabetes: a 12-week randomized clinical trial. PLoS One. 2016;11(6):e0155918. doi:10.1371/journal.pone.0155918.PubMedPubMedCentralCrossRef

29.

Yokoyama Y, Barnard ND, Levin SM, Watanabe M. Vegetarian diets and glycemic control in diabetes: a systematic review and meta-analysis. Cardiovasc Diagn Ther. 2014;4(5):373–82. doi:10.3978/j.issn.2223-3652.2014.10.04.PubMedPubMedCentral

30.

Liese AD, Nichols M, Sun X, D'Agostino RB Jr, Haffner SM. Adherence to the DASH diet is inversely associated with incidence of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2009;32(8):1434–6. doi:10.2337/dc09-0228.PubMedPubMedCentralCrossRef

31.

• Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014;37(Supplement 1):S120–S43. This is a position statement by the American Diabetes Association (ADA) outlining its recommendations for nutrition therapy in adults with diabetes PubMedCrossRef

32.

Burger KN, Beulens JW, van der Schouw YT, Sluijs I, Spijkerman AM, Sluik D, et al. Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS One. 2012;7(8):e43127. doi:10.1371/journal.pone.0043127.PubMedPubMedCentralCrossRef

33.

Parillo M, Annuzzi G, Rivellese AA, Bozzetto L, Alessandrini R, Riccardi G, et al. Effects of meals with different glycaemic index on postprandial blood glucose response in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. Diabetic medicine : a journal of the British Diabetic Association. 2011;28(2):227–9. doi:10.1111/j.1464-5491.2010.03176.x.CrossRef

34.

Wheeler ML, Dunbar SA, Jaacks LM, Karmally W, Mayer-Davis EJ, Wylie-Rosett J, et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. Diabetes Care. 2012;35(2):434–45. doi:10.2337/dc11-2216.PubMedPubMedCentralCrossRef

35.

Franz MJ, Boucher JL, Evert AB. Evidence-based diabetes nutrition therapy recommendations are effective: the key is individualization. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:65–72. doi:10.2147/dmso.s45140.CrossRef

36.

Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90. doi:10.1056/NEJMoa1200303.PubMedCrossRef

37.

Miller CT, Fraser SF, Levinger I, Straznicky NE, Dixon JB, Reynolds J, et al. The effects of exercise training in addition to energy restriction on functional capacities and body composition in obese adults during weight loss: a systematic review. PLoS One. 2013;8(11):e81692. doi:10.1371/journal.pone.0081692.PubMedPubMedCentralCrossRef

38.

Washburn RA, Szabo AN, Lambourne K, Willis EA, Ptomey LT, Honas JJ, et al. Does the method of weight loss effect long-term changes in weight, body composition or chronic disease risk factors in overweight or obese adults? A systematic review. PLoS One. 2014;9(10):e109849. doi:10.1371/journal.pone.0109849.PubMedPubMedCentralCrossRef

39.

Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 2012;55(3):542–51. doi:10.1007/s00125-011-2403-2.PubMedCrossRef

40.

Fuchsjäger-Mayrl G, Pleiner J, Wiesinger GF, Sieder AE, Quittan M, Nuhr MJ, et al. Exercise training improves vascular endothelial function in patients with type 1 diabetes. Diabetes Care. 2002;25(10):1795–801. doi:10.2337/diacare.25.10.1795.PubMedCrossRef

41.

Hawley JA. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab Res Rev. 2004;20(5):383–93. doi:10.1002/dmrr.505.PubMedCrossRef

42.

Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Church TS. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis. 2014;56(4):441–7. doi:10.1016/j.pcad.2013.09.012.PubMedCrossRef

43.

Ismail I, Keating SE, Baker MK, Johnson NA. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat. Obesity Reviews: an Official Journal of the International Association for the Study of Obesity. 2012;13(1):68–91. doi:10.1111/j.1467-789X.2011.00931.x.CrossRef

44.

Hunter GR, Byrne NM, Sirikul B, Fernandez JR, Zuckerman PA, Darnell BE, et al. Resistance training conserves fat-free mass and resting energy expenditure following weight loss. Obesity (Silver Spring). 2008;16(5):1045–51. doi:10.1038/oby.2008.38.CrossRef

45.

Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenburg J, Nilwik R, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc. 2013;14(8):585–92. doi:10.1016/j.jamda.2013.02.006.PubMedCrossRef

46.

Heydari M, Freund J, Boutcher SH. The effect of high-intensity intermittent exercise on body composition of overweight young males. J Obes. 2012;2012:480467. doi:10.1155/2012/480467.PubMedPubMedCentralCrossRef

47.

Madsen SM, Thorup AC, Overgaard K, Jeppesen PB. High intensity interval training improves glycaemic control and pancreatic β cell function of type 2 diabetes patients. PLoS One. 2015;10(8):e0133286. doi:10.1371/journal.pone.0133286.PubMedPubMedCentralCrossRef

48.

Trapp E, Chisholm D, Freund J, Boutcher S. The effects of high-intensity intermittent exercise training on fat loss and fasting insulin levels of young women. Int J Obes. 2008;32(4):684–91.CrossRef

49.

Keating SE, Machan EA, O'Connor HT, Gerofi JA, Sainsbury A, Caterson ID, et al. Continuous exercise but not high intensity interval training improves fat distribution in overweight adults. J Obes. 2014;2014:834865. doi:10.1155/2014/834865.PubMedPubMedCentralCrossRef

50.

Rabasa-Lhoret R, Bourque J, Ducros F, Chiasson JL. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care. 2001;24(4):625–30.PubMedCrossRef

51.

•• Riddell MC, Gallen IW, Smart CE, Taplin CE, Adolfsson P, Lumb AN, et al. Exercise management in type 1 diabetes: a consensus statement. The Lancet Diabetes & Endocrinology. 2017;5(5):377–90. doi:10.1016/s2213-8587(17)30014-1. This review provides new recommendations for exercise management in patients with T1D CrossRef

52.

Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8(5):573–84. doi:10.1517/14740330903081725.PubMedCrossRef

53.

Dornhorst A, Luddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008;62(4):659–65. doi:10.1111/j.1742-1241.2008.01715.x.PubMedCrossRef

54.

Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327(20):1426–33. doi:10.1056/nejm199211123272005.PubMedCrossRef

55.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet (London, England). 2012;379(9825):1489–97. doi:10.1016/s0140-6736(12)60204-9.CrossRef

56.

Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154–62. doi:10.1210/jc.2012-3249.PubMedPubMedCentralCrossRef

57.

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217–25. doi:10.2337/dc15-0249.PubMedCrossRef

58.

Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2005;11(1):11–7. doi:10.4158/ep.11.1.11.CrossRef

59.

Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clinical Science (London, England: 1979). 2012;122(6):253–70. doi:10.1042/cs20110386.CrossRef

60.

Burchardt P, Zawada A, Tabaczewski P, Naskret D, Kaczmarek J, Marcinkaniec J, et al. Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized lowdensity lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. Polskie Archiwum Medycyny Wewnetrznej. 2013;123(10):526–32.PubMed

61.

•• Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. The Lancet Diabetes & endocrinology. 2017; doi:10.1016/s2213-8587(17)30194-8. This study describes long-term outcomes of metformin use in adults with T1D

62.

Holst JJ. Incretin hormones and the satiation signal. International Journal of Obesity (2005). 2013;37(9):1161–8. doi:10.1038/ijo.2012.208.

63.

Dejgaard TF, Frandsen CS, Holst JJ, Madsbad S. Liraglutide for treating type 1 diabetes. Expert Opin Biol Ther. 2016;16(4):579–90. doi:10.1517/14712598.2016.1160050.PubMedCrossRef

64.

•• Janzen KM, Steuber TD, Nisly SA. GLP-1 agonists in type 1 diabetes mellitus. Ann Pharmacother. 2016;50(8):656–65. doi:10.1177/1060028016651279. This article reviews all trials to date that used GLP-1 analogs in patients with T1D PubMedCrossRef

65.

Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, et al. Liraglutide as additional treatment for type 1 diabetes. European Journal of Endocrinology/European Federation of Endocrine Societies. 2011;165(1):77–84. doi:10.1530/eje-11-0330.CrossRef

66.

Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54. doi:10.1056/NEJMoa1212914.PubMedCrossRef

67.

Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011;34(7):1463–8. doi:10.2337/dc11-0096.PubMedPubMedCentralCrossRef

68.

Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care. 2014;37(1):210–6. doi:10.2337/dc13-1169.PubMedCrossRef

69.

Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes. 2014;38(4):269–72. doi:10.1016/j.jcjd.2013.10.006.PubMedCrossRef

70.

Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55–8. doi:10.1016/j.diabres.2013.01.020.PubMedCrossRef

71.

Thule PM. Mechanisms of current therapies for diabetes mellitus type 2. Adv Physiol Educ. 2012;36(4):275–83. doi:10.1152/advan.00094.2012.PubMedPubMedCentralCrossRef

72.

• Herrmann K, Brunell SC, Li Y, Zhou M, Maggs DG. Impact of disease duration on the effects of pramlintide in type 1 diabetes: a post hoc analysis of three clinical trials. Adv Ther. 2016;33(5):848–61. doi:10.1007/s12325-016-0326-5. This study describes the effects of pramlintide treatment in patients with T1D across a wide range of disease duration PubMedPubMedCentralCrossRef

73.

Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017; doi:10.1016/j.cmet.2017.04.011.

74.

Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. American Journal of Physiology Renal physiology. 2015;309(11):F889–900. doi:10.1152/ajprenal.00267.2015.PubMedPubMedCentral

75.

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72. doi:10.1161/circulationaha.116.021887.PubMedCrossRef

76.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. doi:10.1056/NEJMoa1611925.

77.

Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480–3. doi:10.2337/dc13-2338.PubMedCrossRef

78.

Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412–9. doi:10.2337/dc13-2955.PubMedCrossRef

79.

• Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38(7):1181–8. doi:10.2337/dc14-2806. This study reports significant body weight reduction and improvement in glycemic control among patients with T1D treated with the SGLT2 inhibitor sotagliflozin PubMedPubMedCentralCrossRef

80.

Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med. 2016;129(8):879.e1–6. doi:10.1016/j.amjmed.2016.02.009.CrossRef

81.

O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–36. doi:10.1038/oby.2012.66.CrossRef

82.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308. doi:10.3945/ajcn.111.024927.PubMedCrossRef

83.

Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9. doi:10.2337/dc13-0234.PubMedPubMedCentralCrossRef

84.

Vasas P, Por F. Surgical options for reducing body weight. Orv Hetil. 2014;155(25):971–7. doi:10.1556/oh.2014.29844.PubMedCrossRef

85.

Gill RS, Majumdar SR, Rueda-Clausen CF, Apte S, Birch DW, Karmali S, et al. Comparative effectiveness and safety of gastric bypass, sleeve gastrectomy and adjustable gastric banding in a population-based bariatric program: prospective cohort study. Canadian journal of surgery Journal canadien de chirurgie. 2016;59(4):13315. doi:10.1503/cjs.013315.CrossRef

86.

Praveenraj P, Gomes RM, Kumar S, Perumal S, Senthilnathan P, Parthasarathi R, et al. Comparison of weight loss outcomes 1 year after sleeve gastrectomy and Roux-en-Y gastric bypass in patients aged above 50 years. Journal of minimal access surgery. 2016;12(3):220–5. doi:10.4103/0972-9941.183481.PubMedPubMedCentralCrossRef

87.

Adams TD, Arterburn DE, Nathan DM, Eckel RH. Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care. 2016;39(6):912–23. doi:10.2337/dc16-0157.PubMedPubMedCentralCrossRef

88.

Lee SK, Heo Y, Park JM, Kim YJ, Kim SM, Park do J, et al. Roux-en-Y gastric bypass vs. sleeve gastrectomy vs. gastric banding: the first multicenter retrospective comparative cohort study in obese Korean patients. Yonsei Med J. 2016;57(4):956–62. doi:10.3349/ymj.2016.57.4.956.PubMedPubMedCentralCrossRef

89.

Grubnik VV, Ospanov OB, Namaeva KA, Medvedev OV, Kresyun MS. Randomized controlled trial comparing laparoscopic greater curvature plication versus laparoscopic sleeve gastrectomy. Surg Endosc. 2016;30(6):2186–91. doi:10.1007/s00464-015-4373-9.PubMedCrossRef

90.

Lager CJ, Esfandiari NH, Subauste AR, Kraftson AT, Brown MB, Cassidy RB, et al. Roux-en-Y gastric bypass vs. sleeve gastrectomy: balancing the risks of surgery with the benefits of weight loss. Obes Surg. 2017;27(1):154–61. doi:10.1007/s11695-016-2265-2.PubMedCrossRef

91.

Sabbagh C, Verhaeghe P, Dhahri A, Brehant O, Fuks D, Badaoui R, et al. Two-year results on morbidity, weight loss and quality of life of sleeve gastrectomy as first procedure, sleeve gastrectomy after failure of gastric banding and gastric banding. Obes Surg. 2010;20(6):679–84. doi:10.1007/s11695-009-0007-4.PubMedCrossRef

92.

Purnell JQ, Selzer F, Wahed AS, Pender J, Pories W, Pomp A, et al. Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: results of the longitudinal assessment of bariatric surgery study. Diabetes Care. 2016;39(7):1101–7. doi:10.2337/dc15-2138.PubMedPubMedCentralCrossRef

93.

•• Kirwan JP, Aminian A, Kashyap SR, Burguera B, Brethauer SA, Schauer PR. Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care. 2016;39(6):941–8. doi:10.2337/dc15-2732. A review of bariatric surgery outcomes conducted in patients with T1D and obesity PubMedCrossRef

94.

Abdeen G, le Roux CW. Mechanism underlying the weight loss and complications of Roux-en-Y gastric bypass. Review Obes Surg. 2016;26(2):410–21. doi:10.1007/s11695-015-1945-7.PubMedCrossRef

95.

Holst JJ. Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide 1. Diabetes. 2011;60(9):2203–5. doi:10.2337/db11-0798.PubMedPubMedCentralCrossRef

96.

Holst JJ, Madsbad S. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery. 2016;12(6):1236–42. doi:10.1016/j.soard.2016.02.033.CrossRef

97.

Kratz M, Hagman DK, Kuzma JN, Foster-Schubert KE, Chan CP, Stewart S, et al. Improvements in glycemic control after gastric bypass occur despite persistent adipose tissue inflammation. Obesity (Silver Spring). 2016;24(7):1438–45. doi:10.1002/oby.21524.CrossRef

98.

Smith BR, Hinojosa MW, Reavis KM, Nguyen NT. Remission of diabetes after laparoscopic gastric bypass. Am Surg. 2008;74(10):948–52.PubMed

99.

Dixon JB, Chuang LM, Chong K, Chen SC, Lambert GW, Straznicky NE, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36(1):20–6. doi:10.2337/dc12-0779.PubMedCrossRef

100.

Hara M, Fowler JL, Bell GI, Philipson LH. Resting beta-cells—a functional reserve? Diabetes & Metabolism. 2016;42(3):157–61. doi:10.1016/j.diabet.2016.01.001.CrossRef

101.

Celio AC, Wu Q, Kasten KR, Manwaring ML, Pories WJ, Spaniolas K. Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy in super obese patients. Surg Endosc. 2017;31(1):317–23. doi:10.1007/s00464-016-4974-y.PubMedCrossRef

102.

Nannipieri M, Belligoli A, Guarino D, Busetto L, Moriconi D, Fabris R, et al. Risk factors for spontaneously self-reported postprandial hypoglycemia after bariatric surgery. J Clin Endocrinol Metab. 2016;101(10):3600–7. doi:10.1210/jc.2016-1143.PubMedCrossRef

103.

Felsenreich DM, Langer FB, Kefurt R, Panhofer P, Schermann M, Beckerhinn P, et al. Weight loss, weight regain, and conversions to Roux-en-Y gastric bypass: 10-year results of laparoscopic sleeve gastrectomy. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery. 2016;12(9):1655–62. doi:10.1016/j.soard.2016.02.021.CrossRef

104.

Lalor PF, Tucker ON, Szomstein S, Rosenthal RJ. Complications after laparoscopic sleeve gastrectomy. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery. 2008;4(1):33–8. doi:10.1016/j.soard.2007.08.015.CrossRef

105.

Yildiz B, Katar K, Hamamci O. Efficacy of laparoscopic sleeve gastrectomy for the treatment of obesity in a non-western society. Eating and Weight Disorders: EWD. 2016;21(4):695–9. doi:10.1007/s40519-016-0287-3.PubMedCrossRef

106.

Shah N, Greenberg JA, Leverson G, Statz AK, Jolles SA, Funk LM. Weight loss after bariatric surgery: a propensity score analysis. J Surg Res. 2016;202(2):449–54. doi:10.1016/j.jss.2016.01.041.PubMedCrossRef

107.

Faucher P, Poitou C, Carette C, Tezenas du Montcel S, Barsamian C, Touati E, et al. Bariatric surgery in obese patients with type 1 diabetes: effects on weight loss and metabolic control. Obes Surg. 2016;26(10):2370–8. doi:10.1007/s11695-016-2106-3.PubMedCrossRef

108.

Lannoo M, Dillemans B, Van Nieuwenhove Y, Fieuws S, Mathieu C, Gillard P, et al. Bariatric surgery induces weight loss but does not improve glycemic control in patients with type 1 diabetes. Diabetes Care. 2014;37(8):e173–4. doi:10.2337/dc14-0583.PubMedCrossRef

109.

Maraka S, Kudva YC, Kellogg TA, Collazo-Clavell ML, Mundi MS. Bariatric surgery and diabetes: implications of type 1 versus insulin-requiring type 2. Obesity (Silver Spring). 2015;23(3):552–7. doi:10.1002/oby.20992.CrossRef

Title: Weight Management in Patients with Type 1 Diabetes and Obesity
Authors: Adham Mottalib
Megan Kasetty
Jessica Y. Mar
Taha Elseaidy
Sahar Ashrafzadeh
Osama Hamdy
Publication date: 01-10-2017
Publisher: Springer US
Published in: Current Diabetes Reports / Issue 10/2017
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-017-0918-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 10/2017

Intraocular Inflammation in Diabetic Populations

The Role of Epigenetics in Type 1 Diabetes

Diameter Changes of Retinal Vessels in Diabetic Retinopathy

Shared Dysregulation of Homeostatic Brain-Body Pathways in Depression and Type 2 Diabetes

Tolerogenic Nanoparticles to Treat Islet Autoimmunity

Deciphering the Pathogenesis of Human Type 1 Diabetes (T1D) by Interrogating T Cells from the “Scene of the Crime”

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage